Pliant Therapeutics (PLRX) Other Accumulated Expenses (2021 - 2026)

Pliant Therapeutics (PLRX) has 6 years of Other Accumulated Expenses data on file, last reported at $4.1 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $4.1 million, down 71.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 71.21% YoY), and the FY2025 annual result was $4.8 million, down 66.55% from the prior year.
• Other Accumulated Expenses fell to $4.1 million in Q1 2026 per PLRX's latest filing, from $4.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $23.0 million in Q3 2024 and troughed at $4.1 million in Q1 2026.
• A 5-year average of $13.2 million and a median of $14.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses jumped 91.17% in 2022, then slumped 71.21% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $11.2 million in 2022, then rose by 11.04% to $12.5 million in 2023, then rose by 15.31% to $14.4 million in 2024, then sank by 66.55% to $4.8 million in 2025, then slipped by 13.8% to $4.1 million in 2026.
• Business Quant data shows PLRX's Other Accumulated Expenses at $4.1 million in Q1 2026, $4.8 million in Q4 2025, and $7.8 million in Q3 2025.